Hypertrophic Cardiomyopathy: Genetics, Pathogenesis, Clinical Manifestations, Diagnosis, and Therapy.
暂无分享,去创建一个
[1] M. Entman,et al. Angiotensin II Blockade Reverses Myocardial Fibrosis in a Transgenic Mouse Model of Human Hypertrophic Cardiomyopathy , 2001, Circulation.
[2] P. Elliott,et al. Prevalence of Anderson–Fabry disease in patients with hypertrophic cardiomyopathy: the European Anderson–Fabry Disease Survey , 2011, Heart.
[3] J. Potter,et al. Familial Hypertrophic Cardiomyopathy Mutations from Different Functional Regions of Troponin T Result in Different Effects on the pH and Ca2+ Sensitivity of Cardiac Muscle Contraction* , 2004, Journal of Biological Chemistry.
[4] L. Maquat,et al. Leveraging Rules of Nonsense-Mediated mRNA Decay for Genome Engineering and Personalized Medicine , 2016, Cell.
[5] D. Waggoner,et al. Sarcomere Mutations in Cardiomyopathy With Left Ventricular Hypertrabeculation , 2009, Circulation. Cardiovascular genetics.
[6] Barry J Maron,et al. Hypertrophic cardiomyopathy: present and future, with translation into contemporary cardiovascular medicine. , 2014, Journal of the American College of Cardiology.
[7] J B Patlak,et al. Hypertrophic and dilated cardiomyopathy mutations differentially affect the molecular force generation of mouse alpha-cardiac myosin in the laser trap assay. , 2007, American journal of physiology. Heart and circulatory physiology.
[8] E. Braunwald,et al. Chronic beta adrenergic receptor blockade in the treatment of idiopathic hypertrophic subaortic stenosis. , 1968, Progress in cardiovascular diseases.
[9] R. Omar,et al. Prediction of thrombo‐embolic risk in patients with hypertrophic cardiomyopathy (HCM Risk‐CVA) , 2015, European journal of heart failure.
[10] B. Gersh,et al. Atrial Fibrillation in Hypertrophic Cardiomyopathy: Prevalence, Clinical Correlations, and Mortality in a Large High‐Risk Population , 2014, Journal of the American Heart Association.
[11] F O Mueller,et al. Sudden death in young competitive athletes. Clinical, demographic, and pathological profiles. , 1996, JAMA.
[12] A. Blamire,et al. Hypertrophic cardiomyopathy due to sarcomeric gene mutations is characterized by impaired energy metabolism irrespective of the degree of hypertrophy. , 2003, Journal of the American College of Cardiology.
[13] A. Tajik,et al. Myosin binding protein C mutations and compound heterozygosity in hypertrophic cardiomyopathy. , 2004, Journal of the American College of Cardiology.
[14] A. Dart,et al. Circulating microRNAs as biomarkers for diffuse myocardial fibrosis in patients with hypertrophic cardiomyopathy , 2015, Journal of Translational Medicine.
[15] Jeroen J. Bax,et al. Left Atrial Size and Function in Hypertrophic Cardiomyopathy Patients and Risk of New-Onset Atrial Fibrillation , 2017, Circulation. Arrhythmia and electrophysiology.
[16] P. Elliott,et al. Idiopathic restrictive cardiomyopathy is part of the clinical expression of cardiac troponin I mutations. , 2003, The Journal of clinical investigation.
[17] J. Gardin,et al. Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults. , 1995, Circulation.
[18] M. Quiñones,et al. Evolution of expression of cardiac phenotypes over a 4-year period in the beta-myosin heavy chain-Q403 transgenic rabbit model of human hypertrophic cardiomyopathy. , 2004, Journal of molecular and cellular cardiology.
[19] J. Seidman,et al. Expression and functional assessment of a truncated cardiac troponin T that causes hypertrophic cardiomyopathy. Evidence for a dominant negative action. , 1996, The Journal of clinical investigation.
[20] H Niimura,et al. Mutations in the gene for cardiac myosin-binding protein C and late-onset familial hypertrophic cardiomyopathy. , 1998, The New England journal of medicine.
[21] F. T. ten Cate,et al. Perturbed Length-Dependent Activation in Human Hypertrophic Cardiomyopathy With Missense Sarcomeric Gene Mutations , 2013, Circulation research.
[22] A. Marian,et al. Antifibrotic effects of antioxidant N-acetylcysteine in a mouse model of human hypertrophic cardiomyopathy mutation. , 2006, Journal of the American College of Cardiology.
[23] K. Thangaraj,et al. Mechanistic Heterogeneity in Contractile Properties of α-Tropomyosin (TPM1) Mutants Associated with Inherited Cardiomyopathies* , 2014, The Journal of Biological Chemistry.
[24] Shobha Vasudevan,et al. Non-stop decay--a new mRNA surveillance pathway. , 2002, BioEssays : news and reviews in molecular, cellular and developmental biology.
[25] S. Abbara,et al. Effects of losartan on left ventricular hypertrophy and fibrosis in patients with nonobstructive hypertrophic cardiomyopathy. , 2013, JACC. Heart failure.
[26] J. Spudich,et al. Effects of Troponin T Cardiomyopathy Mutations on the Calcium Sensitivity of the Regulated Thin Filament and the Actomyosin Cross-Bridge Kinetics of Human β-Cardiac Myosin , 2013, PloS one.
[27] C. Bustamante,et al. Multidimensional structure-function relationships in human β-cardiac myosin from population-scale genetic variation , 2016, Proceedings of the National Academy of Sciences.
[28] A. Marian,et al. Sudden cardiac death in hypertrophic cardiomyopathy. Variability in phenotypic expression of beta-myosin heavy chain mutations. , 1995, European heart journal.
[29] C. Autore,et al. Risk of sudden death and outcome in patients with hypertrophic cardiomyopathy with benign presentation and without risk factors. , 2014, The American journal of cardiology.
[30] S. Cook,et al. Defining the genetic architecture of hypertrophic cardiomyopathy: re-evaluating the role of non-sarcomeric genes , 2017, European heart journal.
[31] W. McKenna,et al. Hypertrophic cardiomyopathy — pathology and pathogenesis , 1995, Histopathology.
[32] Sanjay Shete,et al. Genome-wide mapping of modifier chromosomal loci for human hypertrophic cardiomyopathy. , 2007, Human molecular genetics.
[33] A. Kimura. Molecular genetics and pathogenesis of cardiomyopathy , 2015, Journal of Human Genetics.
[34] B. Gersh,et al. Genotype-Phenotype Correlations in Apical Variant Hypertrophic Cardiomyopathy. , 2015, Congenital heart disease.
[35] R. Shephard. Sudden Deaths in Young Competitive Athletes: Analysis of 1866 Deaths in the United States, 1980–2006 , 2010 .
[36] A. Briasoulis,et al. Myocardial fibrosis on cardiac magnetic resonance and cardiac outcomes in hypertrophic cardiomyopathy: a meta-analysis , 2015, Heart.
[37] A. Marian,et al. Differential interactions of thin filament proteins in two cardiac troponin T mouse models of hypertrophic and dilated cardiomyopathies. , 2008, Cardiovascular research.
[38] S. Shete,et al. Myozenin 2 Is a Novel Gene for Human Hypertrophic Cardiomyopathy , 2007, Circulation research.
[39] S. Nagueh,et al. Molecular, cellular, and functional characterization of myocardial regions in hypertrophic cardiomyopathy. , 2012, Circulation. Cardiovascular imaging.
[40] H. Watkins,et al. Normal passive viscoelasticity but abnormal myofibrillar force generation in human hypertrophic cardiomyopathy , 2010, Journal of molecular and cellular cardiology.
[41] S. Ommen,et al. Mutations in JPH2-encoded junctophilin-2 associated with hypertrophic cardiomyopathy in humans. , 2007, Journal of molecular and cellular cardiology.
[42] Stefan Neubauer,et al. Differentiation of athlete's heart from pathological forms of cardiac hypertrophy by means of geometric indices derived from cardiovascular magnetic resonance. , 2004, Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance.
[43] M. Quiñones,et al. Tissue Doppler Imaging Predicts the Development of Hypertrophic Cardiomyopathy in Subjects With Subclinical Disease , 2003, Circulation.
[44] M. Entman,et al. Dominant-negative effect of a mutant cardiac troponin T on cardiac structure and function in transgenic mice. , 1998, The Journal of clinical investigation.
[45] B. Gelb,et al. Cardiomyopathies in Noonan syndrome and the other RASopathies. , 2015, Progress in pediatric cardiology.
[46] E. Braunwald,et al. IDIOPATHIC MYOCARDIAL HYPERTROPHY WITHOUT CONGESTIVE HEART FAILURE OR OBSTRUCTION TO BLOOD FLOW. CLINICAL, HEMODYNAMIC AND ANGIOCARDIOGRAPHIC STUDIES IN FOURTEEN PATIENTS. , 1963, The American journal of medicine.
[47] J. Seidman,et al. Mutations in the genes for cardiac troponin T and alpha-tropomyosin in hypertrophic cardiomyopathy. , 1995, The New England journal of medicine.
[48] P. Elliott,et al. Non-sustained ventricular tachycardia in hypertrophic cardiomyopathy: an independent marker of sudden death risk in young patients. , 2003, Journal of the American College of Cardiology.
[49] A. Marian. Nature's genetic gradients and the clinical phenotype. , 2009, Circulation. Cardiovascular genetics.
[50] B. Maron,et al. Prevalence of hypertrophic cardiomyopathy in an outpatient population referred for echocardiographic study. , 1994, The American journal of cardiology.
[51] J. Seidman,et al. Clinical features of hypertrophic cardiomyopathy caused by mutation of a "hot spot" in the alpha-tropomyosin gene. , 1997, Journal of the American College of Cardiology.
[52] F. Pagani,et al. Sarcomere Mutation-Specific Expression Patterns in Human Hypertrophic Cardiomyopathy , 2014, Circulation. Cardiovascular genetics.
[53] M. Matsuzaki,et al. Mutations in the cardiac troponin I gene associated with hypertrophic cardiomyopathy , 1997, Nature Genetics.
[54] E. Braunwald,et al. Impaired Rate of Left Ventricular Filling in Idiopathic Hypertrophic Subaortic Stenosis and Valvular Aortic Stenosis , 1968, Circulation.
[55] K. Ueda,et al. Identification and functional analysis of a caveolin-3 mutation associated with familial hypertrophic cardiomyopathy. , 2004, Biochemical and biophysical research communications.
[56] H. Trappe,et al. Two-dimensional strain analysis of the global and regional myocardial function for the differentiation of pathologic and physiologic left ventricular hypertrophy: a study in athletes and in patients with hypertrophic cardiomyopathy , 2010, The International Journal of Cardiovascular Imaging.
[57] M. Komajda,et al. Diagnostic value of electrocardiography and echocardiography for familial hypertrophic cardiomyopathy in a genotyped adult population. , 1997, Circulation.
[58] S. Gabriel,et al. Burden of rare sarcomere gene variants in the Framingham and Jackson Heart Study cohorts. , 2012, American journal of human genetics.
[59] D. MacArthur,et al. Reassessment of Mendelian gene pathogenicity using 7,855 cardiomyopathy cases and 60,706 reference samples , 2016, Genetics in Medicine.
[60] Christine E. Seidman,et al. Allele-Specific Silencing of Mutant Myh6 Transcripts in Mice Suppresses Hypertrophic Cardiomyopathy , 2013, Science.
[61] A. Fayssoil. Prognostic implications of the Doppler restrictive filling pattern in hypertrophic cardiomyopathy. , 2010, The American journal of cardiology.
[62] R. Desnick,et al. Long-term safety and efficacy of enzyme replacement therapy for Fabry disease. , 2004, American journal of human genetics.
[63] W. Henry,et al. Asymmetric Septal Hypertrophy: Echocardiographic Identification of the Pathognomonic Anatomic Abnormality of IHSS , 1973, Circulation.
[64] A. Marian,et al. Sudden cardiac death in hypertrophic cardiomyopathy , 1995 .
[65] M. Bainbridge,et al. A Potential Oligogenic Etiology of Hypertrophic Cardiomyopathy: A Classic Single-Gene Disorder , 2017, Circulation research.
[66] T. Sakamoto,et al. Prevalence of hypertrophic cardiomyopathy in a population of adult Japanese workers as detected by echocardiographic screening. , 1987 .
[67] B. Maron,et al. Sudden Deaths in Young Competitive Athletes: Analysis of 1866 Deaths in the United States, 1980–2006 , 2009, Circulation.
[68] U. Bavendiek,et al. Blood-based microRNA signatures differentiate various forms of cardiac hypertrophy. , 2015, International journal of cardiology.
[69] A. Keren,et al. Prevalence of exercise-induced left ventricular outflow tract obstruction in symptomatic patients with non-obstructive hypertrophic cardiomyopathy , 2007, Heart.
[70] A. Børglum,et al. Alpha-cardiac actin is a novel disease gene in familial hypertrophic cardiomyopathy. , 1999, The Journal of clinical investigation.
[71] N. Pandian,et al. Hypertrophic Cardiomyopathy with Right Ventricular Outflow Tract and Left Ventricular Intracavitary Obstruction , 2014, Echocardiography.
[72] L. Axel,et al. Regional Heterogeneity of Function in Hypertrophic Cardiomyopathy , 1994, Circulation.
[73] M. Quiñones,et al. Simvastatin Induces Regression of Cardiac Hypertrophy and Fibrosis and Improves Cardiac Function in a Transgenic Rabbit Model of Human Hypertrophic Cardiomyopathy , 2001, Circulation.
[74] Eugene Berezikov,et al. A Deep Sequencing Approach to Uncover the miRNOME in the Human Heart , 2013, PloS one.
[75] M. Quiñones,et al. Angiotensin-I converting enzyme genotypes and left ventricular hypertrophy in patients with hypertrophic cardiomyopathy. , 1995, Circulation.
[76] F. T. ten Cate,et al. MicroRNA transcriptome profiling in cardiac tissue of hypertrophic cardiomyopathy patients with MYBPC3 mutations. , 2013, Journal of molecular and cellular cardiology.
[77] R. Sinke,et al. Biallelic Truncating Mutations in ALPK3 Cause Severe Pediatric Cardiomyopathy. , 2016, Journal of the American College of Cardiology.
[78] Theodore P Abraham,et al. The Burden of Early Phenotypes and the Influence of Wall Thickness in Hypertrophic Cardiomyopathy Mutation Carriers: Findings From the HCMNet Study , 2017, JAMA cardiology.
[79] Christine E. Seidman,et al. α-tropomyosin and cardiac troponin T mutations cause familial hypertrophic cardiomyopathy: A disease of the sarcomere , 1994, Cell.
[80] A. Tajik,et al. Risk of death in long-term follow-up of patients with apical hypertrophic cardiomyopathy. , 2013, The American journal of cardiology.
[81] Steven B Marston,et al. How do MYBPC3 mutations cause hypertrophic cardiomyopathy? , 2011, Journal of Muscle Research and Cell Motility.
[82] M. Laakso,et al. Low-grade inflammation and the phenotypic expression of myocardial fibrosis in hypertrophic cardiomyopathy , 2012, Heart.
[83] J. Potter,et al. Clinical and Functional Characterization of TNNT2 Mutations Identified in Patients With Dilated Cardiomyopathy , 2009, Circulation. Cardiovascular genetics.
[84] R. Solaro,et al. Molecular mechanisms of cardiac myofilament activation: modulation by pH and a troponin T mutant R92Q , 2002, Basic Research in Cardiology.
[85] B. Maron,et al. Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy. , 2005, Journal of the American College of Cardiology.
[86] M. Entman,et al. Aldosterone, Through Novel Signaling Proteins, Is a Fundamental Molecular Bridge Between the Genetic Defect and the Cardiac Phenotype of Hypertrophic Cardiomyopathy , 2004, Circulation.
[87] H. Katus,et al. Repair of Mybpc3 mRNA by 5′-trans-splicing in a Mouse Model of Hypertrophic Cardiomyopathy , 2013, Molecular therapy. Nucleic acids.
[88] A. Marian. Pathogenesis of diverse clinical and pathological phenotypes in hypertrophic cardiomyopathy , 2000, The Lancet.
[89] H. Watkins,et al. Evidence From Human Myectomy Samples That MYBPC3 Mutations Cause Hypertrophic Cardiomyopathy Through Haploinsufficiency* , 2009, Circulation research.
[90] M. Sheppard,et al. Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy using cardiovascular magnetic resonance , 2010 .
[91] K. Hayashi,et al. Compound heterozygosity deteriorates phenotypes of hypertrophic cardiomyopathy with founder MYBPC3 mutation: evidence from patients and zebrafish models. , 2014, American journal of physiology. Heart and circulatory physiology.
[92] J. Moolman-Smook,et al. Troponin T and beta-myosin mutations have distinct cardiac functional effects in hypertrophic cardiomyopathy patients without hypertrophy. , 2008, Cardiovascular research.
[93] E. Braunwald,et al. Hemogynamic alterations in idiopathic hypertrophic subaortic stenosis induced by sympathomimetic drugs. , 1962, The American journal of cardiology.
[94] Jianwen Wang,et al. Atorvastatin and cardiac hypertrophy and function in hypertrophic cardiomyopathy: a pilot study , 2010, European journal of clinical investigation.
[95] A. Børglum,et al. α-cardiac actin is a novel disease gene in familial hypertrophic cardiomyopathy , 1999 .
[96] H. Watkins,et al. Mutations in cis can confound genotype-phenotype correlations in hypertrophic cardiomyopathy , 2001, Journal of medical genetics.
[97] M. Chiariello,et al. Myocardial Collagen Turnover in Hypertrophic Cardiomyopathy , 2003, Circulation.
[98] B. Maron,et al. Differentiating left ventricular hypertrophy in athletes from that in patients with hypertrophic cardiomyopathy. , 2014, The American journal of cardiology.
[99] Life Technologies,et al. A map of human genome variation from population-scale sequencing , 2011 .
[100] W. Rottbauer,et al. Novel splice donor site mutation in the cardiac myosin-binding protein-C gene in familial hypertrophic cardiomyopathy. Characterization Of cardiac transcript and protein. , 1997, The Journal of clinical investigation.
[101] C. Lambrew,et al. Idiopathic Hypertrophic Subaortic Stenosis: I. A Description of the Disease Based Upon an Analysis of 64 Patients , 1964, Circulation.
[102] P. Elliott,et al. Prevalence of Sarcomere Protein Gene Mutations in Preadolescent Children With Hypertrophic Cardiomyopathy , 2008, Circulation. Cardiovascular genetics.
[103] J. Neutze,et al. Inheritance of hypertrophic cardiomyopathy: a cross sectional and M mode echocardiographic study of 50 families. , 1987, British heart journal.
[104] J. Boeke,et al. SDH1, the gene encoding the succinate dehydrogenase flavoprotein subunit from Saccharomyces cerevisiae. , 1992, Gene.
[105] M. Komajda,et al. Organization and sequence of human cardiac myosin binding protein C gene (MYBPC3) and identification of mutations predicted to produce truncated proteins in familial hypertrophic cardiomyopathy. , 1997, Circulation research.
[106] T. Edvardsen,et al. Increased amount of interstitial fibrosis predicts ventricular arrhythmias, and is associated with reduced myocardial septal function in patients with obstructive hypertrophic cardiomyopathy. , 2013, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.
[107] Masahiko Hoshijima,et al. Tcap gene mutations in hypertrophic cardiomyopathy and dilated cardiomyopathy. , 2004, Journal of the American College of Cardiology.
[108] M. Quiñones,et al. Tissue Doppler Imaging Consistently Detects Myocardial Abnormalities in Patients With Hypertrophic Cardiomyopathy and Provides a Novel Means for an Early Diagnosis Before and Independently of Hypertrophy , 2001, Circulation.
[109] J. Seidman,et al. Compound and double mutations in patients with hypertrophic cardiomyopathy: implications for genetic testing and counselling , 2005, Journal of Medical Genetics.
[110] B. Brenner,et al. Familial hypertrophic cardiomyopathy: functional effects of myosin mutation R723G in cardiomyocytes. , 2013, Journal of molecular and cellular cardiology.
[111] L. Leinwand,et al. Myosin heavy chain isoform expression in the failing and nonfailing human heart. , 2000, Circulation research.
[112] M. Link,et al. Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy. , 2007, JAMA.
[113] Gabor T. Marth,et al. A global reference for human genetic variation , 2015, Nature.
[114] M. Gautel,et al. A newly created splice donor site in exon 25 of the MyBP-C gene is responsible for inherited hypertrophic cardiomyopathy with incomplete disease penetrance. , 2000, Circulation.
[115] R. Schwinger,et al. Alterations of Tension-dependent ATP Utilization in a Transgenic Rat Model of Hypertrophic Cardiomyopathy* , 2006, Journal of Biological Chemistry.
[116] Frederick J. Schoen,et al. A Mouse Model of Familial Hypertrophic Cardiomyopathy , 1996, Science.
[117] L. García,et al. Rescue of cardiomyopathy through U7snRNA-mediated exon skipping in Mybpc3-targeted knock-in mice , 2013, EMBO molecular medicine.
[118] S. Colan,et al. Myocardial fibrosis as an early manifestation of hypertrophic cardiomyopathy. , 2010, The New England journal of medicine.
[119] A. Dziembowski,et al. Proteins involved in the degradation of cytoplasmic mRNA in the major eukaryotic model systems , 2014, RNA biology.
[120] B. Brenner,et al. Unequal allelic expression of wild-type and mutated β-myosin in familial hypertrophic cardiomyopathy , 2011, Basic Research in Cardiology.
[121] A. Marian,et al. Causality in genetics: the gradient of genetic effects and back to Koch's postulates of causality. , 2014, Circulation research.
[122] A. Marian,et al. Detection of a new mutation in the beta-myosin heavy chain gene in an individual with hypertrophic cardiomyopathy. , 1992, The Journal of clinical investigation.
[123] B. Nadal-Ginard,et al. Expression of the cardiac ventricular alpha- and beta-myosin heavy chain genes is developmentally and hormonally regulated. , 1984, The Journal of biological chemistry.
[124] M. Devoto,et al. Genetic heterogeneity of hypertrophic cardiomyopathy. , 1985, International journal of cardiology.
[125] F. Rutten,et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). , 2014, European heart journal.
[126] R. Brugada,et al. Role of candidate modifier genes on the phenotypic expression of hypertrophy in patients with hypertrophic cardiomyopathy. , 1997, Journal of investigative medicine : the official publication of the American Federation for Clinical Research.
[127] Perry M Elliott,et al. A systematic review and meta-analysis of genotype–phenotype associations in patients with hypertrophic cardiomyopathy caused by sarcomeric protein mutations , 2013, Heart.
[128] J. Moon,et al. Update on hypertrophic cardiomyopathy and a guide to the guidelines , 2016, Nature Reviews Cardiology.
[129] P. Kellman,et al. Myocardial Fibrosis Quantified by Extracellular Volume Is Associated With Subsequent Hospitalization for Heart Failure, Death, or Both Across the Spectrum of Ejection Fraction and Heart Failure Stage , 2015, Journal of the American Heart Association.
[130] Y. Nishimura,et al. Downregulation of GSTK1 Is a Common Mechanism Underlying Hypertrophic Cardiomyopathy , 2016, Front. Pharmacol..
[131] Eloisa Arbustini,et al. Evidence for FHL1 as a novel disease gene for isolated hypertrophic cardiomyopathy. , 2012, Human molecular genetics.
[132] C. Nienaber,et al. Syncope in hypertrophic cardiomyopathy: multivariate analysis of prognostic determinants. , 1990, Journal of the American College of Cardiology.
[133] A. Marian,et al. Angiotensin-converting enzyme polymorphism in hypertrophic cardiomyopathy and sudden cardiac death , 1993, The Lancet.
[134] S. Heymans,et al. Mutations in MYH7 reduce the force generating capacity of sarcomeres in human familial hypertrophic cardiomyopathy. , 2013, Cardiovascular research.
[135] M. Link,et al. Contemporary Natural History and Management of Nonobstructive Hypertrophic Cardiomyopathy. , 2016, Journal of the American College of Cardiology.
[136] M. Link,et al. Hypertrophic Cardiomyopathy Is Predominantly a Disease of Left Ventricular Outflow Tract Obstruction , 2006, Circulation.
[137] Akshay S. Desai,et al. The Design of the Valsartan for Attenuating Disease Evolution in Early Sarcomeric Hypertrophic Cardiomyopathy (VANISH) Trial , 2017, American heart journal.
[138] A J Marian,et al. Strategic approaches to unraveling genetic causes of cardiovascular diseases. , 2011, Circulation research.
[139] A. Marian,et al. Pathogenesis of hypertrophic cardiomyopathy caused by myozenin 2 mutations is independent of calcineurin activity. , 2013, Cardiovascular research.
[140] P. Elliott,et al. Atrial fibrillation and thromboembolism in patients with hypertrophic cardiomyopathy: systematic review , 2013, Heart.
[141] M. Link,et al. Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. , 2000, The New England journal of medicine.
[142] M. Eriksson,et al. Long-term outcome in patients with apical hypertrophic cardiomyopathy. , 2002, Journal of the American College of Cardiology.
[143] S. Nagueh,et al. Prevention of Cardiac Hypertrophy by Atorvastatin in a Transgenic Rabbit Model of Human Hypertrophic Cardiomyopathy , 2005, Circulation research.
[144] Giuseppe Limongelli,et al. A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM risk-SCD). , 2014, European heart journal.
[145] P. Elliott,et al. Prevalence of Anderson-Fabry Disease in Male Patients With Late Onset Hypertrophic Cardiomyopathy , 2002, Circulation.
[146] A. Marian. Hypertrophic cardiomyopathy: from genetics to treatment , 2010, European journal of clinical investigation.
[147] D. Pennell,et al. Reproducibility of in-vivo diffusion tensor cardiovascular magnetic resonance in hypertrophic cardiomyopathy , 2012, Journal of Cardiovascular Magnetic Resonance.
[148] J. Seidman,et al. Haploinsufficiency of MYBPC3 exacerbates the development of hypertrophic cardiomyopathy in heterozygous mice. , 2015, Journal of molecular and cellular cardiology.
[149] Christine E. Seidman,et al. A small-molecule inhibitor of sarcomere contractility suppresses hypertrophic cardiomyopathy in mice , 2016, Science.
[150] B. Maron,et al. Double or compound sarcomere mutations in hypertrophic cardiomyopathy: a potential link to sudden death in the absence of conventional risk factors. , 2012, Heart rhythm.
[151] Michael J Ackerman,et al. Clinical features and outcome of hypertrophic cardiomyopathy associated with triple sarcomere protein gene mutations. , 2010, Journal of the American College of Cardiology.
[152] P. Brink,et al. MYBPH acts as modifier of cardiac hypertrophy in hypertrophic cardiomyopathy (HCM) patients , 2016, Human Genetics.
[153] T. Hewett,et al. A truncated cardiac troponin T molecule in transgenic mice suggests multiple cellular mechanisms for familial hypertrophic cardiomyopathy. , 1998, The Journal of clinical investigation.
[154] Hyuk-Jae Chang,et al. Fabry disease in patients with hypertrophic cardiomyopathy: a practical approach to diagnosis , 2016, Journal of Human Genetics.
[155] B. Maron,et al. Impact of Atrial Fibrillation on the Clinical Course of Hypertrophic Cardiomyopathy , 2001, Circulation.
[156] P. Elliott,et al. Cardiac Myosin Binding Protein-C Mutations in Families With Hypertrophic Cardiomyopathy: Disease Expression in Relation to Age, Gender, and Long Term Outcome , 2012, Circulation. Cardiovascular genetics.
[157] B. Maron,et al. Hypertrophic Cardiomyopathy in Children, Adolescents, and Young Adults Associated With Low Cardiovascular Mortality With Contemporary Management Strategies , 2016, Circulation.
[158] M. Komajda,et al. Hypertrophic Cardiomyopathy: Distribution of Disease Genes, Spectrum of Mutations, and Implications for a Molecular Diagnosis Strategy , 2003, Circulation.
[159] J. Brugada,et al. Differentiating hypertrophic cardiomyopathy from athlete's heart: An electrocardiographic and echocardiographic approach. , 2016, Journal of electrocardiology.
[160] Wei Yang,et al. Microarray profiling of long non-coding RNA (lncRNA) associated with hypertrophic cardiomyopathy , 2015, BMC Cardiovascular Disorders.
[161] J. Mariani,et al. Evaluating the Utility of Circulating Biomarkers of Collagen Synthesis in Hypertrophic Cardiomyopathy , 2014, Circulation. Heart failure.
[162] Matthew S. Lebo,et al. Results of clinical genetic testing of 2,912 probands with hypertrophic cardiomyopathy: expanded panels offer limited additional sensitivity , 2015, Genetics in Medicine.
[163] M. Link,et al. Prevention of sudden cardiac death with implantable cardioverter-defibrillators in children and adolescents with hypertrophic cardiomyopathy. , 2013, Journal of the American College of Cardiology.
[164] W. Roberts,et al. Intramural ("small vessel") coronary artery disease in hypertrophic cardiomyopathy. , 1986, Journal of the American College of Cardiology.
[165] W. Chan,et al. A double-blind, placebo-controlled crossover trial of nadolol and verapamil in mild and moderately symptomatic hypertrophic cardiomyopathy. , 1993, Journal of the American College of Cardiology.
[166] J. Ross,et al. Effects of Beta Adrenergic Blockade on the Circulation, with Particular Reference to Observations in Patients with Hypertrophic Subaortic Stenosis , 1964, Circulation.
[167] W. Chung,et al. RAAS gene polymorphisms influence progression of pediatric hypertrophic cardiomyopathy , 2007, Human Genetics.
[168] James O. Mudd,et al. An abnormal Ca(2+) response in mutant sarcomere protein-mediated familial hypertrophic cardiomyopathy. , 2000, The Journal of clinical investigation.
[169] B. Brenner,et al. Hypertrophic Cardiomyopathy: Cell-to-Cell Imbalance in Gene Expression and Contraction Force as Trigger for Disease Phenotype Development. , 2016, Circulation research.
[170] M. Russo,et al. Prevalence of Fabry Disease in Female Patients With Late-Onset Hypertrophic Cardiomyopathy , 2004, Circulation.
[171] B. Maron,et al. β Blockers for prevention of exercise-induced left ventricular outflow tract obstruction in patients with hypertrophic cardiomyopathy. , 2012, The American journal of cardiology.
[172] E. Braunwald,et al. Functional Aortic Stenosis: A Malformation Characterized by Resistance to Left Ventricular Outflow without Anatomic Obstruction , 1959, Circulation.
[173] E. Antman,et al. Diltiazem treatment for pre-clinical hypertrophic cardiomyopathy sarcomere mutation carriers: a pilot randomized trial to modify disease expression. , 2015, JACC. Heart failure.
[174] C. Hengstenberg,et al. Familial hypertrophic cardiomyopathy. Microsatellite haplotyping and identification of a hot spot for mutations in the beta-myosin heavy chain gene. , 1993, The Journal of clinical investigation.
[175] 北村 聖. "The New England Journal of Medicine". , 1962, British medical journal.
[176] M. Davies. The current status of myocardial disarray in hypertrophic cardiomyopathy. , 1984, British heart journal.
[177] M. Entman,et al. Decreased left ventricular ejection fraction in transgenic mice expressing mutant cardiac troponin T-Q(92), responsible for human hypertrophic cardiomyopathy. , 2000, Journal of molecular and cellular cardiology.
[178] G. Boivin,et al. An internal domain of beta-tropomyosin increases myofilament Ca(2+) sensitivity. , 2009, American journal of physiology. Heart and circulatory physiology.
[179] A. Tajik,et al. Modern Imaging Techniques in Cardiomyopathies. , 2017, Circulation research.
[180] L. Jordaens,et al. Implantable cardioverter-defibrillators in hypertrophic cardiomyopathy: patient outcomes, rate of appropriate and inappropriate interventions, and complications. , 2013, American heart journal.
[181] W. Chung,et al. Short Communication: The Cardiac Myosin Binding Protein C Arg502Trp Mutation: A Common Cause of Hypertrophic Cardiomyopathy , 2010, Circulation research.
[182] J. Ross,et al. The Circulatory Response of Patients with Idiopathic Hypertrophic Subaortic Stenosis to Nitroglycerin and to the Valsalva Maneuver , 1964, Circulation.
[183] J. Seidman,et al. 5'RNA-Seq identifies Fhl1 as a genetic modifier in cardiomyopathy. , 2014, The Journal of clinical investigation.
[184] Structural Analysis of the Titin Gene in Hypertrophic Cardiomyopathy : Identification of a Novel Disease Gene , 2000 .
[185] C. Moravec,et al. Human cardiac myosin heavy chain isoforms in fetal and failing adult atria and ventricles. , 2001, American journal of physiology. Heart and circulatory physiology.
[186] M. Link,et al. Hypertrophic Cardiomyopathy in Adulthood Associated With Low Cardiovascular Mortality With Contemporary Management Strategies. , 2015, Journal of the American College of Cardiology.
[187] Y. Lecarpentier,et al. Myosin isoenzymic distribution correlates with speed of myocardial contraction. , 1981, Journal of molecular and cellular cardiology.
[188] S. Ommen,et al. Molecular and functional characterization of novel hypertrophic cardiomyopathy susceptibility mutations in TNNC1-encoded troponin C. , 2007, Journal of molecular and cellular cardiology.
[189] J. Seidman,et al. Characteristics and prognostic implications of myosin missense mutations in familial hypertrophic cardiomyopathy. , 1992, The New England journal of medicine.
[190] M. Latronico,et al. Circulating miR-29a, among other up-regulated microRNAs, is the only biomarker for both hypertrophy and fibrosis in patients with hypertrophic cardiomyopathy. , 2014, Journal of the American College of Cardiology.
[191] Peter Nürnberg,et al. Beyond the sarcomere: CSRP3 mutations cause hypertrophic cardiomyopathy. , 2008, Human molecular genetics.
[192] B. Maron,et al. Spectrum and prognostic significance of arrhythmias on ambulatory Holter electrocardiogram in hypertrophic cardiomyopathy. , 2005, Journal of the American College of Cardiology.
[193] A. Marian. Challenges in the Diagnosis of Anderson-Fabry Disease: A Deceptively Simple and Yet Complicated Genetic Disease. , 2016, Journal of the American College of Cardiology.
[194] S. Ommen,et al. PLN-encoded phospholamban mutation in a large cohort of hypertrophic cardiomyopathy cases: summary of the literature and implications for genetic testing. , 2011, American heart journal.
[195] Barry J Maron,et al. New perspectives on the prevalence of hypertrophic cardiomyopathy. , 2015, Journal of the American College of Cardiology.
[196] Euan A Ashley,et al. Abnormal calcium handling properties underlie familial hypertrophic cardiomyopathy pathology in patient-specific induced pluripotent stem cells. , 2013, Cell stem cell.
[197] M. Geeves,et al. Myosin isoforms and the mechanochemical cross-bridge cycle , 2016, Journal of Experimental Biology.
[198] P. Elliott,et al. Hypertrophic Cardiomyopathy: Histopathological Features of Sudden Death in Cardiac Troponin T Disease , 2001, Circulation.
[199] W. Williams,et al. Overexpression of transforming growth factor-beta1 and insulin-like growth factor-I in patients with idiopathic hypertrophic cardiomyopathy. , 1997, Circulation.
[200] M Hiroe,et al. Structural analysis of the titin gene in hypertrophic cardiomyopathy: identification of a novel disease gene. , 1999, Biochemical and biophysical research communications.
[201] L. Leinwand,et al. The Hypertrophic Cardiomyopathy Myosin Mutation R453C Alters ATP Binding and Hydrolysis of Human Cardiac β-Myosin* , 2013, The Journal of Biological Chemistry.
[202] Kathryn A. O’Donnell,et al. An mRNA Surveillance Mechanism That Eliminates Transcripts Lacking Termination Codons , 2002, Science.
[203] H. Schaff,et al. Hypertrophic Obstructive Cardiomyopathy: Surgical Myectomy and Septal Ablation , 2017, Circulation research.
[204] K. Lindenberg,et al. Impairment of the ubiquitin-proteasome system by truncated cardiac myosin binding protein C mutants. , 2005, Cardiovascular research.
[205] R. Porcher,et al. Prevalence and spectrum of mutations in a cohort of 192 unrelated patients with hypertrophic cardiomyopathy. , 2010, European journal of medical genetics.
[206] H. Matsubara,et al. Analysis of circulating apoptosis mediators and proinflammatory cytokines in patients with idiopathic hypertrophic cardiomyopathy: comparison between nonobstructive and dilated-phase hypertrophic cardiomyopathy. , 2005, International heart journal.
[207] R. Brock. Functional obstruction of the left ventricle (acquired aortic subvalvar stenosis). , 1959, Guy's Hospital reports.
[208] L. Carrier,et al. Cardiac myosin-binding protein C in hypertrophic cardiomyopathy: mechanisms and therapeutic opportunities. , 2011, Journal of molecular and cellular cardiology.
[209] H. Watkins,et al. Mutations of the Light Meromyosin Domain of the &bgr;-Myosin Heavy Chain Rod in Hypertrophic Cardiomyopathy , 2002, Circulation research.
[210] I. Rayment,et al. Mutations in either the essential or regulatory light chains of myosin are associated with a rare myopathy in human heart and skeletal muscle , 1996, Nature Genetics.
[211] A J Marian,et al. A transgenic rabbit model for human hypertrophic cardiomyopathy. , 1999, The Journal of clinical investigation.
[212] G. Bonsel,et al. Risk stratification for sudden cardiac death in hypertrophic cardiomyopathy: systematic review of clinical risk markers. , 2010, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.
[213] A. van Rossum,et al. Gene-specific increase in the energetic cost of contraction in hypertrophic cardiomyopathy caused by thick filament mutations. , 2014, Cardiovascular research.
[214] K. Siminovitch,et al. Toronto Hypertrophic Cardiomyopathy Genotype Score for Prediction of a Positive Genotype in Hypertrophic Cardiomyopathy , 2013, Circulation. Cardiovascular genetics.
[215] S. Prabhu,et al. Diffuse Ventricular Fibrosis on Cardiac Magnetic Resonance Imaging Associates With Ventricular Tachycardia in Patients With Hypertrophic Cardiomyopathy , 2016, Journal of cardiovascular electrophysiology.
[216] D. G. MacArthur,et al. Guidelines for investigating causality of sequence variants in human disease , 2014, Nature.
[217] J. Skinner,et al. A Prospective Study of Sudden Cardiac Death among Children and Young Adults. , 2016, The New England journal of medicine.
[218] R. L. Lekanne Deprez,et al. Two cases of severe neonatal hypertrophic cardiomyopathy caused by compound heterozygous mutations in the MYBPC3 gene , 2006, Journal of Medical Genetics.
[219] P. Knight,et al. Cardiomyopathy Mutations in the Tail of β-Cardiac Myosin Modify the Coiled-coil Structure and Affect Integration into Thick Filaments in Muscle Sarcomeres in Adult Cardiomyocytes* , 2013, The Journal of Biological Chemistry.
[220] B. Maron,et al. Clinical profile of hypertrophic cardiomyopathy identified de novo in rural communities. , 1999, Journal of the American College of Cardiology.
[221] Roger R Markwald,et al. Cardiac fibrosis in mice with hypertrophic cardiomyopathy is mediated by non-myocyte proliferation and requires Tgf-β. , 2010, The Journal of clinical investigation.
[222] David M. Warshaw,et al. Understanding Cardiomyopathy Phenotypes Based on the Functional Impact of Mutations in the Myosin Motor , 2012, Circulation research.
[223] R. Hui,et al. Prevalence of idiopathic hypertrophic cardiomyopathy in China: a population-based echocardiographic analysis of 8080 adults. , 2004, The American journal of medicine.
[224] M. Yacoub,et al. Codon 102 of the cardiac troponin T gene is a putative hot spot for mutations in familial hypertrophic cardiomyopathy. , 1996, Circulation.
[225] Francisco J. Alvarado,et al. Genotype-Dependent and -Independent Calcium Signaling Dysregulation in Human Hypertrophic Cardiomyopathy , 2016, Circulation.
[226] Pamela R. Fain,et al. α-Myosin Heavy Chain: A Sarcomeric Gene Associated With Dilated and Hypertrophic Phenotypes of Cardiomyopathy , 2005, Circulation.
[227] H. Katus,et al. Mybpc3 gene therapy for neonatal cardiomyopathy enables long-term disease prevention in mice , 2014, Nature Communications.
[228] M. Simoons,et al. Cardiac beta-myosin heavy chain defects in two families with non-compaction cardiomyopathy: linking non-compaction to hypertrophic, restrictive, and dilated cardiomyopathies. , 2007, European heart journal.
[229] J. Seidman,et al. Sarcomere Protein Gene Mutations in Hypertrophic Cardiomyopathy of the Elderly , 2002, Circulation.
[230] Natesa G Pandian,et al. Investigation of Global and Regional Myocardial Mechanics With 3-Dimensional Speckle Tracking Echocardiography and Relations to Hypertrophy and Fibrosis in Hypertrophic Cardiomyopathy , 2014, Circulation. Cardiovascular imaging.
[231] Y. Pinto,et al. Genetic advances in sarcomeric cardiomyopathies: state of the art , 2015, Cardiovascular research.
[232] P. Elliott,et al. Sudden death in hypertrophic cardiomyopathy: identification of high risk patients. , 2000, Journal of the American College of Cardiology.
[233] D. Altshuler,et al. A map of human genome variation from population-scale sequencing , 2010, Nature.
[234] J. Kautzner,et al. Isolated X-Linked Hypertrophic Cardiomyopathy Caused by a Novel Mutation of the Four-and-a-Half LIM Domain 1 Gene , 2013, Circulation. Cardiovascular genetics.
[235] Raffaella Lombardi,et al. Human Molecular Genetic and Functional Studies Identify TRIM63, Encoding Muscle RING Finger Protein 1, as a Novel Gene for Human Hypertrophic Cardiomyopathy , 2012, Circulation research.
[236] E. W. Hancock,et al. Muscular Subaortic Stenosis: Prevention of Outflow Obstruction with Propranolol , 1968, Circulation.
[237] W. Manning,et al. Mitral valve abnormalities identified by cardiovascular magnetic resonance represent a primary phenotypic expression of hypertrophic cardiomyopathy , 2010, Circulation.
[238] F. Weinberger,et al. Increased myofilament Ca2+ sensitivity and diastolic dysfunction as early consequences of Mybpc3 mutation in heterozygous knock-in mice , 2012, Journal of molecular and cellular cardiology.
[239] F. T. ten Cate,et al. Cardiac Myosin-Binding Protein C Mutations and Hypertrophic Cardiomyopathy: Haploinsufficiency, Deranged Phosphorylation, and Cardiomyocyte Dysfunction , 2009, Circulation.
[240] R. G. Fraser,et al. Hereditary cardiovascular dysplasia. A form of familial cardiomyopathy. , 1961, The American journal of medicine.
[241] S. Solomon,et al. Mutations in sarcomere protein genes as a cause of dilated cardiomyopathy. , 2001, The New England journal of medicine.
[242] V. Regitz-Zagrosek,et al. Mutation spectrum in a large cohort of unrelated consecutive patients with hypertrophic cardiomyopathy , 2003, Clinical genetics.
[243] J. Seidman,et al. A Tension-Based Model Distinguishes Hypertrophic versus Dilated Cardiomyopathy , 2016, Cell.
[244] L. Tiret,et al. Evidence, from combined segregation and linkage analysis, that a variant of the angiotensin I-converting enzyme (ACE) gene controls plasma ACE levels. , 1992, American journal of human genetics.
[245] J. Seidman,et al. A molecular basis for familial hypertrophic cardiomyopathy: A β cardiac myosin heavy chain gene missense mutation , 1990, Cell.
[246] E. Ashley,et al. Clinical Phenotype and Outcome of Hypertrophic Cardiomyopathy Associated With Thin-Filament Gene Mutations , 2014, Journal of the American College of Cardiology.
[247] E. Braunwald,et al. Nonobstructive Hypertrophic Cardiomyopathy Out of the Shadows: Known from the Beginning but Largely Ignored … Until Now. , 2017, The American journal of medicine.
[248] F. Marín,et al. Serum levels of high-sensitivity troponin T: a novel marker for cardiac remodeling in hypertrophic cardiomyopathy. , 2010, Journal of cardiac failure.
[249] A. Marian. On genetic and phenotypic variability of hypertrophic cardiomyopathy: nature versus nurture. , 2001, Journal of the American College of Cardiology.
[250] N. Alpert,et al. Altered Myosin Isozyme Patterns from Pressure‐ Overloaded and Thyrotoxic Hypertrophied Rabbit Hearts , 1982, Circulation research.
[251] A. Marian. The Case of "Missing Causal Genes" and the Practice of Medicine: A Sherlock Holmes Approach of Deductive Reasoning. , 2016, Circulation research.
[252] James O. Mudd,et al. An abnormal Ca2+ response in mutant sarcomere protein–mediated familial hypertrophic cardiomyopathy , 2000 .
[253] D TEARE,et al. ASYMMETRICAL HYPERTROPHY OF THE HEART IN YOUNG ADULTS , 1958, British heart journal.
[254] H. Mabuchi,et al. A novel mutation Lys273Glu in the cardiac troponin T gene shows high degree of penetrance and transition from hypertrophic to dilated cardiomyopathy. , 2002, The American journal of cardiology.
[255] T. Arimura,et al. Screening of sarcomere gene mutations in young athletes with abnormal findings in electrocardiography: identification of a MYH7 mutation and MYBPC3 mutations , 2015, Journal of Human Genetics.
[256] Mathew G. Wilson,et al. Comparison of Electrocardiographic Criteria for the Detection of Cardiac Abnormalities in Elite Black and White Athletes , 2014, Circulation.